Tuesday, March 17, 2009

Cinryze Infusion Reverses Plasma Activation In Hereditary Angioedema

Cinryze Infusion Reverses Plasma Activation In Hereditary Angioedema
WASHINGTON DC - New data show that replacement therapy with Cinryze (C1 inhibitor-nf) infusion reverses all abnormalities of the plasma bradykinin-forming pathway and fibrinolysis that are responsible for the swelling attacks in patients with hereditary angioedema (HAE).